Fig. 2.
Temporal assessment of tumor volume in Raji-xenografted mice that were untreated or treated with 125 μCi (4.625 MBq)90Y-DOTA-peptide-Lym-1 (RIT) alone, anti-CD22 alone (HB22.7), or 3 different sequences of RIT and HB22.7 (CMIT) in all trials and include HB22.7 administered 24 h prior to RIT (−24), simultaneous with RIT (@RIT), or 24 h after RIT (+24).
Tumor volume was assessed 3 times per week. Mouse numbers for each treatment group are tabulated (Table 2).
